Key result
Compared with multifactorial chylomicronemia syndrome, familial chylomicronemia syndrome was associated with a 3-fold higher incidence rate of acute pancreatitis and higher on-treatment triglycerides.
Why the study?
Familial and multifactorial chylomicronemia syndromes have been only partially investigated, leaving a systematic comparison of their genetic profiles and clinical outcomes incomplete.
Do genetic profiles and clinical outcomes differ between familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS) in patients with severe hypertriglyceridemia?
Cohort (n=32)
Do genetic profiles and clinical outcomes differ between familial chylomicronemia syndrome (FCS) and multifactorial chylomicronemia syndrome (MCS) in patients with severe hypertriglyceridemia?
No takes yet. Share an insight, caveat, or question.
FCS identification may refine pancreatitis risk estimates; leaves open genetic testing impact on outcomes in hypertriglyceridemia.
D’Erasmo et al. (2019) conducted a cohort in Severe hypertriglyceridemia (FCS and MCS) (n=32). Familial chylomicronemia syndrome (FCS) vs. Multifactorial chylomicronemia syndrome (MCS) was evaluated on Clinical outcomes including age of hypertriglyceridemia onset, on-treatment triglycerides, and incidence of acute pancreatitis. Compared with multifactorial chylomicronemia syndrome, familial chylomicronemia syndrome was associated with a 3-fold higher incidence rate of acute pancreatitis and higher on-treatment triglycerides.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: